下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>

Tpg Gp A, Llc Sells 436,431 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) Stock
TPG GP A,LLC出售特雷维治疗公司(纳斯达克代码:TRVI)的436,431股票

Defense World ·  {{timeTz}}

Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Rating) major shareholder Tpg Gp A, Llc sold 436,431 shares of the stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $2.86, for a total value of $1,248,192.66. Following the transaction, the insider now owns 3,888,452 shares in the company, valued at $11,120,972.72. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.

特雷维治疗公司(纳斯达克代码:TRVI-GET评级)的大股东TPG GP A,LLC在7月1日星期五的一笔交易中出售了436,431股该股票。这只股票的平均售价为2.86美元,总价值为1248,192.66美元。交易完成后,这位内部人士现在拥有该公司3888,452股,价值11,120,972.72美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,通过这个链接可以访问该文件。持有公司至少10%股份的大股东必须披露他们与美国证券交易委员会的交易。

Tpg Gp A, Llc also recently made the following trade(s):

TPG GP A,LLC最近还进行了以下交易:

Get
到达
Trevi Therapeutics
特雷维治疗公司
alerts:
警报:
  • On Tuesday, July 5th, Tpg Gp A, Llc sold 63,569 shares of Trevi Therapeutics stock. The stock was sold at an average price of $3.11, for a total value of $197,699.59.
  • On Wednesday, June 29th, Tpg Gp A, Llc sold 46,128 shares of Trevi Therapeutics stock. The stock was sold at an average price of $2.74, for a total value of $126,390.72.
  • On Monday, May 2nd, Tpg Gp A, Llc sold 600 shares of Trevi Therapeutics stock. The stock was sold at an average price of $2.70, for a total value of $1,620.00.
  • On Thursday, April 28th, Tpg Gp A, Llc sold 7,271 shares of Trevi Therapeutics stock. The stock was sold at an average price of $2.77, for a total value of $20,140.67.
  • 7月5日,星期二,TPG GP A,LLC出售了63,569股Trevi治疗公司的股票。这只股票的平均售价为3.11美元,总价值为197699.59美元。
  • 6月29日,星期三,TPG GP A,LLC出售了46,128股Trevi Treeutics股票。这只股票的平均售价为2.74美元,总价值为126,390.72美元。
  • 5月2日,星期一,TPG GP A,LLC出售了600股Trevi治疗公司的股票。这只股票的平均售价为2.70美元,总价值为1,620.00美元。
  • 4月28日,星期四,TPG GP A,LLC出售了7271股Trevi治疗公司的股票。这只股票的平均售价为2.77美元,总价值为20,140.67美元。

NASDAQ TRVI opened at $3.79 on Friday. The firm has a market capitalization of $146.64 million, a P/E ratio of -2.81 and a beta of 0.18. The business has a fifty day simple moving average of $2.40 and a 200 day simple moving average of $1.74. Trevi Therapeutics, Inc. has a 12 month low of $0.46 and a 12 month high of $3.86. The company has a current ratio of 2.32, a quick ratio of 2.32 and a debt-to-equity ratio of 0.67.

纳斯达克TRVI上周五开盘报3.79美元。该公司市值为1.4664亿美元,市盈率为-2.81,贝塔系数为0.18。该业务的50日简单移动均线切入位为2.40美元,200日简单移动均线切入位为1.74美元。Trevi Treeutics,Inc.的12个月低点为0.46美元,12个月高位为3.86美元。该公司的流动比率为2.32,速动比率为2.32,债务权益比率为0.67。

Trevi Therapeutics (NASDAQ:TRVI – Get Rating) last released its quarterly earnings results on Thursday, May 12th. The company reported ($0.24) EPS for the quarter, beating analysts' consensus estimates of ($0.31) by $0.07. During the same period in the previous year, the business earned ($0.43) earnings per share. As a group, sell-side analysts predict that Trevi Therapeutics, Inc. will post -0.81 EPS for the current fiscal year.
特雷维治疗公司(纳斯达克代码:TRVI-GET Rating)最近一次发布季度收益报告是在5月12日星期四。该公司公布本季度每股收益(0.24美元),比分析师普遍预期的(0.31美元)高出0.07美元。去年同期,该业务实现每股收益(0.43美元)。作为一个整体,卖方分析师预测,Trevi治疗公司本财年的每股收益将达到0.81美元。

Institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Trevi Therapeutics by 7.6% during the 1st quarter. Vanguard Group Inc. now owns 152,831 shares of the company's stock valued at $336,000 after purchasing an additional 10,780 shares during the last quarter. State Street Corp purchased a new stake in shares of Trevi Therapeutics during the 1st quarter valued at $81,000. Virtu Financial LLC purchased a new stake in shares of Trevi Therapeutics during the 1st quarter valued at $44,000. Commonwealth Equity Services LLC purchased a new stake in shares of Trevi Therapeutics during the 1st quarter valued at $33,000. Finally, MAI Capital Management purchased a new stake in shares of Trevi Therapeutics during the 1st quarter valued at $3,391,000. 75.34% of the stock is owned by hedge funds and other institutional investors.

机构投资者最近对他们在该公司的头寸进行了调整。先锋集团第一季度增持Trevi治疗公司股票7.6%。先锋集团目前持有152,831股该公司股票,价值33.6万美元,该公司在上个季度又购买了10,780股。道富银行在第一季度购买了Trevi治疗公司的新股份,价值81,000美元。Virtu Financial LLC在第一季度购买了Trevi治疗公司的新股份,价值4.4万美元。英联邦股权服务有限责任公司在第一季度购买了Trevi治疗公司的新股份,价值3.3万美元。最后,Mai资本管理公司在第一季度购买了Trevi治疗公司的新股份,价值3391,000美元。75.34%的股票由对冲基金和其他机构投资者持有。

A number of equities analysts recently issued reports on the company. Oppenheimer increased their target price on Trevi Therapeutics to $12.00 in a report on Monday. Needham & Company LLC increased their target price on Trevi Therapeutics from $8.00 to $10.00 and gave the stock a "buy" rating in a report on Wednesday, June 29th. Finally, Aegis assumed coverage on Trevi Therapeutics in a research report on Tuesday, March 29th. They issued a "buy" rating and a $10.00 price target for the company.

一些股票分析师最近发布了关于该公司的报告。奥本海默在周一的一份报告中将他们对Trevi治疗公司的目标价上调至12.00美元。Needham&Company LLC在6月29日(星期三)的一份报告中将Trevi Treeutics的目标价从8.00美元上调至10.00美元,并给予该股“买入”评级。最后,宙斯盾在3月29日星期二的一份研究报告中对Trevi治疗公司进行了报道。他们对该公司的评级为“买入”,目标价为10.00美元。

About Trevi Therapeutics (Get Rating)

特雷维治疗公司简介(获取评级)

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis.

Trevi治疗公司是一家临床阶段的生物制药公司,专注于Haduvio的开发和商业化,以治疗严重的神经介导性疾病。该公司正在开发Haduvio,这是一种纳布芬的口服缓释制剂,处于IIb/III期临床试验,用于治疗特发性肺纤维化患者的慢性瘙痒和慢性咳嗽。

Featured Articles

专题文章

  • Get a free copy of the StockNews.com research report on Trevi Therapeutics (TRVI)
  • 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
  • Credo Technology Stock is Rebounding
  • Investing In Preferred Stock vs. Common Stock
  • Profiting From 52 Week Low Stocks
  • Three Cheap Stocks The Insiders Are Buying
  • 免费获取StockNews.com关于特雷维治疗公司(TRVI)的研究报告
  • 3种食品杂货股可以帮助缓解通胀
  • 信实科技股正在反弹
  • 投资优先股与普通股
  • 从52周低点的股票中获利
  • 内部人士正在买入的三只廉价股票

Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

接受Trevi治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Trevi治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。

本页的译文内容由软件翻译。富途将竭力但却不能保证翻译内容之准确和可靠,亦不会承担因任何不准确或遗漏而引起的任何损失或损害。

风险提示:以上内容仅作为作者或者嘉宾的观点,不代表富途的任何立场,不构成与富途相关的任何投资建议。在作出任何投资决定前,投资者应根据自身情况考虑投资产品相关的风险因素,并于需要时咨询专业投资顾问意见。富途竭力但不能证实上述内容的真实性、准确性和原创性,对此富途不做任何保证和承诺。